>

Anita Hauser - Roche Holdings Non-Executive Director

<div class='circular--portrait' style='background:#FCD202;color: white;font-size:3em;padding-top: 40px;;'>RHH</div>
RHHBF -- USA Stock  

USD 344.55  12.60  3.80%

  Director
Ms. Anita Hauser was NonExecutive Independent Director of Roche Holding Ltd since March 14, 2017. She is Member of the Corporationrationrate Governance and Sustainability Committee at the Company.
Age: 49  Director Since 2017      
41 61 688 11 11  http://www.roche.com

Management Efficiency

The company has return on total asset (ROA) of 15.83 % which means that it generated profit of $15.83 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 42.6 % meaning that it generated $42.6 on every $100 dollars invested by stockholders.
The company has accumulated 20.91 B in total debt with debt to equity ratio (D/E) of 43.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Roche Holdings Ag has Current Ratio of 1.27 suggesting that it may have difficulties to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Pierre LandoltNovartis AG
1996
Bonnie BasslerSanofi
2014
Franklyn PrendergastEli Lilly And Company
1995
Nazneen RahmanAstrazeneca PLC
2017
Diane SouzaSanofi
2016
Rebecca HendersonAmgen
2009
Marvinder BangaGlaxoSmithKline PLC
2016
Thomas GlocerMerck Company
2007
Simon DingemansGlaxoSmithKline PLC
2011
Dan LittmanPfizer
2018
Carolyn BertozziEli Lilly And Company
2017
Raul AlvarezEli Lilly And Company
2009
Greg GarlandAmgen
2013
Inge ThulinMerck Company
2018
Robert CastaigneSanofi
N/A
Bernard CharlesSanofi
2017
Deborah DiSanzoAstrazeneca PLC
2017
Ronald WilliamsJohnson Johnson
2011
Rochelle LazarusMerck Company
2004
Ann CairnsAstrazeneca PLC
2014
Jennifer DoudnaJohnson Johnson
2018

Company Summary

Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. The company was founded in 1896 and is headquartered in Basel, Switzerland. Roche Holdings operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 97735 people.Roche Holdings Ag Beare [RHHBF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Roche Holdings Ag Leadership Team

Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of ChugaiView
Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early DevelopmentView
Silvia Ayyoubi, Head of Group HRView
Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche PartneringView
Beatrice Mauro, Non-Executive DirectorView
Cristina Wilbur, Member of the Executive Committee, Head Group Human ResourcesView
William Anderson, Member of the Corporate Executive Committee, CEO Roche PharmaceuticalsView
Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche DiagnosticsView
James Sabry, Member of the Enlarged Corporate Executive Committee, Global Head Pharma PartneringView
Gottlieb Keller, General Counsel and Corporate SecretaryView
Urs Jaisli, Chief Compliance OfficerView
Daniel ODay, COO of Pharmaceuticals divisionView
DeAnne Julius, Non-Executive DirectorView
Karl Mahler, Head of Investor RelationsView
Andre Hoffmann, Non-Executive Vice Chairman of the BoardView
John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early DevelopmentView
Claudia Dyckerhoff, Non-Executive DirectorView
Fritz Gerber, Honorary Chairman of the BoardView
Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group CommunicationsView
Julie Brown, Non-Executive DirectorView
Richard Lifton, Non-Executive DirectorView
Paul Bulcke, Non-Executive DirectorView
Christoph Franz, Non-Executive DirectorView
PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO OfficeView
Pius Baschera, Non-Executive DirectorView
Peter Voser, Non-Executive DirectorView
Bernard Poussot, Non-Executive DirectorView
John Bell, Non-Executive DirectorView
Andreas Oeri, Non-Executive DirectorView
Alan Hippe, CFO and IT OfficerView
William Pao, Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED)View
F Hoffmann, IR Contact OfficerView
Severin Schwan, CEO and DirectorView
Anita Hauser, Non-Executive DirectorView
Michael Heuer, Member of the Corporate Executive Committee, Interim CEO Roche DiagnosticsView

Stock Performance Indicators

Did you try this?

Run Portfolio Holdings Now

   

Portfolio Holdings

Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
All  Next Launch Module

Currently Active Assets on Macroaxis

MSFT   
Purchased few shares of
2 days ago
Traded for 184.77
GM   
Purchased over 70 shares of
2 days ago
Traded for 34.6
MSFT   
Purchased few shares of
2 days ago
Traded for 184.77
C   
Purchased over 30 shares of
2 days ago
Traded for 78.61
GM   
Purchased over 70 shares of
2 days ago
Traded for 34.6
Additionally take a look at Your Equity Center. Please also try Companies Directory module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.